Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial

Clicks: 3
ID: 299420
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #204 of 367 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 367 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We examined the effect of alendronate treatment for 3–4 yr on risk of new fracture among 3658 women with osteoporosis enrolled in the Fracture Intervention Trial. This cohort included women with existing vertebral fracture and those with osteoporosis as defined by T score of less than −2.5 at the femoral neck but without vertebral fracture. All analyses were prespecified in the data analysis plan.
Reference Key
openalex_W2005298224 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dennis M. Black, Desmond Thompson, Douglas C. Bauer, Kristine E. Ensrud, Ming‐Shyan Lin, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, Steven R. Cummings
Journal the journal of clinical endocrinology & metabolism
Year 2000
DOI
10.1210/jcem.85.11.6953
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.